Treating coronary artery disease patients with monotherapy using clopidogrel or ticagrelor was associated with lower rates of ...

An investigation has uncovered evidence of significant misreporting, raising new concerns about the approval and long-term ...

The twice-daily pill is given to people with acute coronary syndrome -a sudden reduction of blood to the heart-reducing the ...

Anti-clotting pill ticagrelor was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack. The twice-daily pill, sold as Brilinta, is given to ...

Medically reviewed by Christopher Lee, MDCoronary artery disease (CAD) occurs when there's a blockage in the arteries that carry blood and oxygen to the heart muscle. CAD is the most common type of ...

Bentracimab rapidly reversed the antiplatelet effects of ticagrelor within 5 to 10 minutes. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute coronary syndrome who had percutaneous ...

After taking ticagrelor and aspirin for 30 days after successful PCI, 1,700 patients were randomly assigned to receive ticagrelor plus aspirin and were followed for 1 year; another group of 1,699 ...

Ticagrelor monotherapy safely cut bleeding by more than half after intervention for acute coronary syndrome, without an increase in MACCE, in the ULTIMATE-DAPT trial.

For patients with acute coronary syndrome (ACS), stopping dual antiplatelet therapy (DAPT) within one month for ticagrelor monotherapy is noninferior and superior to 12 months of ticagrelor-based ...

For patients with a moderate-size stroke, the benefit from ticagrelor plus aspirin is the same as for patients with minor stroke, a new exploratory analysis of the THALES trial shows.